Today, the merger between the two Danish C25-index companies Chr. Hansen and Novozymes was announced.
The proposed transaction will be completed through an all-stock statutory merger, where Chr. Hansen’s shareholders receive approx. 1.53 new shares in Novozymes for each share in Chr. Hansen, corresponding to a premium of 49%. The transaction is supported by Novo Holdings, the controlling shareholder in Novozymes and a major shareholder in Chr. Hansen.
Chr. Hansen is a global, differentiated bioscience company with over 145 years’ experience developing natural ingredient solutions for the food-, nutritional-, pharmaceutical-, and agricultural industries. Novozymes is the world leader in biological solutions and the world’s largest provider of enzyme and microbial technologies.
The combined group would have annual revenue of approximately EUR 3.5bn, employ around 10,000 people and operate a global network of 38 R&D and application centers and 23 manufacturing sites. The transaction , which is subject to approval from regulators and from shareholders in both companies, is expected to be completed between Q4 2023 and Q1 2024.
Get more information from the official press material here.
Gorrissen Federspiel acted as legal advisor to Chr. Hansen. The core transaction team at Gorrissen Federspiel comprises Anders Ørjan Jensen, Tobias Linde and Andreas Hertel (corporate), Martin André Dittmer, Erik Molin and Cecilie Sivertsen (merger control), Niclas Holst Sonne and Anne Becker-Christensen (Danish tax matters), Camilla C. Collet (compliance), Jacob Sand and Rasmus Høj Christensen (executive compensation and employment), Anna Claudius Stadil and Casper Dybbro Andersen.